An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge

Rineke de Jong; Fan Zhou; Tor Kristian Andersen; Norbert Stockhofe-Zurwieden; Rebecca Jane Cox; Bjarne Bogen; Gunnveig Grodeland

doi:10.1038/s41541-025-01341-4

An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge

NPJ Vaccines. 2025 Dec 24;11(1):20. doi: 10.1038/s41541-025-01341-4.

Authors

Rineke de Jong¹, Fan Zhou², Tor Kristian Andersen³, Norbert Stockhofe-Zurwieden¹, Rebecca Jane Cox^{2

4}, Bjarne Bogen^{3

5}, Gunnveig Grodeland^{6

7

8}

Affiliations

¹ Wageningen University and Research, Wageningen Bioveterinary Research, Lelystad, The Netherlands.
² Influenza Centre, Department of Clinical, University of Bergen, Bergen, Norway.
³ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁴ Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
⁵ Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
⁶ Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Gunnveig.grodeland@medisin.uio.no.
⁷ Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. Gunnveig.grodeland@medisin.uio.no.
⁸ Center for Pandemics and One-Health Research, SUSTAINIT, Institute of Health and Society, University of Oslo, Oslo, Norway. Gunnveig.grodeland@medisin.uio.no.

Abstract

Due to antigenic drift and shift, influenza A viruses may cause new future pandemics. Currently used seasonal influenza vaccines are of little use against novel viruses with pandemic potential. Genetic vaccines can be rapidly produced and could therefore mitigate pandemic outbreaks. Here, we present preclinical proof of protective efficacy of a DNA vaccine encoding a vaccine protein that targets influenza hemagglutinin (HA) to human leukocyte antigen class II (HLAII) molecules on antigen presenting cells (APC). Vaccination of mice raised robust levels of neutralizing antibodies, and protection against a lethal challenge with influenza H7N1 virus. In ferrets, we observed induction of neutralizing antibodies and T-cell responses after a single vaccination, with levels increasing after a second dose. Protection of vaccinated ferrets against a viral challenge with influenza H7N9 was dose dependent, with ferrets receiving the highest vaccine dose being completely protected from clinical disease. In sum, these results warrant progression to a human clinical Phase I trial.

Abstract

Grants and funding